Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | LVGN3616 + LVGN6501 + Nab-paclitaxel |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
LVGN3616 | LVGN-3616|LVGN 3616|pradusinstobart | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 121 | LVGN3616 is a humanized monoclonal antibody that targets PD-1 (PDCD1), potentially resulting in restoration of T-cell mediated immune response (NCI Thesaurus). | |
LVGN6501 | LVGN 6501|LVGN-6501 | Limited information is currently available on LVGN6501 (Apr 2023). | ||
Nab-paclitaxel | Abraxane | ABI-007|Paclitaxel Protein-bound | Chemotherapy - Taxane 3 | Abraxane (nab-paclitaxel) is an albumin-stablized version of paclitaxel, which binds microtubules and prevents depolymerization, resulting in decreased cell motility and division (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05075993 | Phase I | Bevacizumab + Cyclophosphamide + LVGN3616 + LVGN6051 + LVGN7409 LVGN3616 + LVGN6051 + LVGN7409 + Nab-paclitaxel Bevacizumab + Cyclophosphamide + LVGN3616 + LVGN6051 LVGN3616 + LVGN6501 + Nab-paclitaxel | Study of LVGN3616 and LVGN6501±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors | Active, not recruiting | USA | 0 |